Proactive Investors - Run By Investors For Investors

Investors urged to take closer look at Astra’s lupus drug trial

Investors urged to take closer look at Astra’s lupus drug trial
Success with the Lupus trial would provide ‘upside’, Deutsche says

Richard Parkes, analyst at Deutsche Bank, reckons AstraZeneca’s (LON:AZN) decision to move its lupus drug candidate into Phase III trials is “worth a second glance” though he acknowledges the news may slip by some investors.

“We believe many investors are likely to overlook AstraZeneca’s latest drug to enter Phase III trials given: (1) the challenging nature of drug development in lupus; (2) the disappointing commercial performance of GSK’s Benlysta; and (3) recent high profile failures of drugs such as UCB’s epratuzumab.

“However, we believe the data is surprisingly encouraging.”

Parkes said the potential new drug doesn’t currently feature as part of Deutsche’s valuation of Astra, and so trial success would represent ‘upside’.

Meanwhile, Deutsche’s Lucas Herrmann described Premier Oil’s (LON:PMO) outlook for 2016 as “a touch disappointing” following the group’s second trading update, though he added that the shares currently appear “inexpensive”.

Stockbroking firm Hargreaves Lansdown reacted to Rolls Royce’s latest profit warning describing it as another major setback.

“Rebuilding confidence in the company’s outlook is now paramount for the relatively new chief executive,” said Hargreaves analyst Keith Bowman.

“For now, despite management changes and a still sizeable order book, current consensus analyst opinion of a weak hold is likely to come under further downward pressure.”

Man Group rating was cut by RBC Capital, which now sees the financial group as ‘sector perform’ rather an ‘outperform’.

Elsewhere, Liberum Capital has downgraded cattle breeding group Genus (LON:GNS) to ‘hold’ from ‘buy’.

Jamie_55a91591db06b.jpg


Register here to be notified of future AZN Company articles

No investment advice: The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use